Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (June 2023)
33 slides from Genelux's investor presentation, Jun 27, 2023
Slide 1: Redefining Immuno-Oncology: Corporate Presentation June 2023
@HeNeELU™x Redefining Immuno-Oncology Corporate Presentation | June 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended, which are subject to the safe harbor” created by those sections, about Gen
Slide 3: Highlights of Genelux Execution
Highlights of Genelux Execution Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICE™ Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgene
Slide 4: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: Engineered to selectively target and eliminate tumor cells while inducing a robust patient-specific immune response Physician-preferred Routes Antitumor Effect Ideal Backbone of of Delivery and Well Tolerated Combination Therapy
Slide 5: Diversified Designs and Indications Exploit Competitive Advantages
Diversified Designs and Indications Exploit Competitive Advantages Olvi-Vec Human Health Design _Preclinical Phase 1 Phase 2 Phase3 _| Collaborators Ovarian Cancer Olwi-Vee (ie) + : ' : un taeuncecnsacen) Cumetbeeey Pha OnPrime/6O6:3076 Study Actively Enrolling aocaee ‘Non-Small Cell Lung Cancer Olv
Slide 6: Selective Replication In Tumors Unleashes Immune System Against Cancer
Selective Replication In Tumors Unleashes Immune System Against Cancer IN Innate Key Takeaways Olvi-Vec is a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body + Kills cancer cells directly + Enhances (neo)antigen pre
Slide 7: Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance
Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance Olvi-Vec-Induced Hot Tumor Pro-therapeutic gene expression Chemotherapy syner} > Positive regulation of T-cell activating munmancsenic cell death and trafficking > Depletion of suppressor cells > Inhibition of anti-virus response \ 4 > I
Slide 8: Over $4 Billion in Transactions in Active Oncolytic Space
Over $4 Billion in Transactions in Active Oncolytic Space @CG CG Oncology raises $120 million in Series E financing to advance clinical-stage urologic oncology pipeline With its recent IPO, Genelux joined the public markets as a Phase 3 company t} Replimune’ Replimune completed a $225 million offeri
Slide 9: Competitive Advantages of Olvi-Vec as an Oncolytic Virus
Compet ive Advantages of Olvi-Vec as an Oncolytic Virus Key Takeaways LN Oncolytic Virus Space Olvi-Vec Key Advantages: Key Players and Assets Olvi-Vec Key Advantages + Broad spectrum of activity Gene Givizves 5 ivi @ target & Treat Metastatic Disease Tumor oy AMGEN. Herpes . seers ree activity / <R
Slide 10: Creating a New Paradigm Of Oncolytic Virus Drug Development
Creating a New Paradigm Of Oncolytic Virus Drug Development Olvi-Vec 7 i New Generati completed clinical trials - Olvi-Vec has the potential to & ENELUX ~150 patients redefine the oncolytic virus space and provide utility across multiple tumor types by enabling physician- preferred administration te
Slide 11: Phase Ib: Anti-tumor Activity as Monotherapy
PI hase Ib: Anti-tumor Activity as Monothera Patient Background & iN Study Treatment Platinum-resistant / refractory ovarian cancer » Heavily pre-treated patients with documented pegtessive) disease at aseline +» Single cycle of high & condensed bolus _ infusions (intraperitoneal lanes) on2 consecut
Slide 12: Completed Phase 2 Tested Olvi-Vec Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec Immunochemothera Olvi-Vec Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer Data Presentations Interventional Single Group Assignment 1. 2020 Digital Annual Meeting of international n=27 Gynecologi
Slide 13: Clinically Meaningful Responses in Heavily Pretreated Patients
Clinically Meaningful Responses in Heavily Pretreated Patients IN Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC’ Key Clinical Takeaways » All patients had documented progressive disease at enrollment * Overall response rate in 27 pat
Slide 14: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage Key Clinical Takeaways Refractory patients performed as well as resistant patients Tumor Shrinkage + Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction + Four patients had 100% reductio
Slide 15: Olvi-Vec-Primed Immunochemotherapy Overcomes Refractoriness
Olvi-Vec-Primed Immunochemothera Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-01; Stage IIIB papillary serous ECOG: 0 BRCA negative PD-Li negative Overall Survival: 23.2 Months + Stage IIB high- grade serou
Slide 16: Durable Benefit of Overall Survival via Clinically-Validated Endpoint
Durable Benefit of Overall Survival via Clinically-Validated Endpoint Key Clinical Takeaways IN 20% long-term survivors consistent with commercially successful immunotherapies + Historical data in 4th line and beyond shows a median overall survival of only 9.8 months + Onamedian Sth line of treatmen
Slide 17: "All-comers" Approach May Reset Life Clock of Heavily Pre-treated Patients
“Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients While clinical remissions are obtainable, a majority of patients will relapse. iN Genelux looks to take an all-comers approach Key Trial Takeaways 100% Sia - 20% i Olvi-Vec addresses a 60% isa broad and underserved we pool of
Slide 18: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment Key Inclusion Criteri: Multi-center, randomized open-label n=186 Primary En
Slide 19: Systemic administration demonstrated dose-dependent OS benefit
stemic administration demonstrated dose-dependent OS benefit Key Trial Takeaways Demonstrated feasibility and clinical benefit of multiple IV cycles * Median 5 prior lines of therapy * Regimen: various dosing levels and schedules ‘typically over 4-6 months, » Well tolerated: no-MTD reached with one
Slide 20: Systemic Administration + Chemo Generated Encouraging Data
Systemic Administration + Chemo Generated Encoura ing Data Key Trial Takeaways Anti-tumor effect of IV Immunochemotherapy + High and Condensed Dosing singe cycle: bolus infusion on5 consecutive ae) * Well tolerated: No DLT or MTD reached ° Menotherapy: Anti-tumor effects » Combination therapy: Virus
Slide 21: Genelux has Partnered with Newsoara BioPharma Co., Ltd
Genelux has Partnered with Newsoara BioPharma Co., Ltd NEWSGARA HIGHLIGHTS 7 5 ENELUX NEWSGARA WREhes Pipelines Phase IIb/III Indications Phase II $850 Million Valuation Top 10 Blue-chip Biotech Investors 2023 Benny Li, PhD Founder and Chief Executive Officer 20+ yrs. global and China local pharma F
Slide 22: Validating Industry Collaboration with Newsoara BioPharma Co., Ltd
Validating Industry Collaboration with Newsoara BioPharma Co., Ltd Key Takeaways IN * Newsoara will fully fund the US-based Genelux Phase 2 trial in NSCLC » Newsoara has development and commercialization rights in Greater China * Phase 2 in NSCLC initial interim readouts expected as early as mid-202
Slide 23: V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical Key Trial Takeaways IN V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy + Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunos
Slide 24: Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch
Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Large-Scale cGMP Manufacturing iN Process to Optimize Production Key Takeaways . Headquarters Westlake Village, CA, USA; independent, Cc controlled 7, 500+ manufacturing facil iy in San Diego to secu material for ivetal studies and
Slide 25: Estimated Billion Dollar Plus Olvi-Vec Commercial Opportunity (US)
Estimated Billion Dollar Plus Olvi-Vec Commercial Opportunity (us) Ovarian Cancer Market* Ovarian Cancer Ovarian Cancer l _Non-Small Cell Lung Cancer| 31.88 » expected CAGR growth ~23.5% Additional revenue drivers: > Re-treatment > Front-Line therapy > Additional Indications, i.e.: women in the US c
Slide 26: Commercial Strategy
Commercial Strategy a = (&) Xe) Be Qe?) Ne Partnerships Self-Manufacturing Patients Reimbursement Leverage partnership Large-Scale cGMP Population without Compelling Value with GOG Foundation Manufacturing Standard of Care Proposition for Payors + Preeminent US-based + Control of Production + PRROC
Slide 27: CHOICE Platform: Engineered and selected clonal isolated (non-GMO) viral strains
Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes therapeutic ) Cell Growth & Differentiation Regulators Hormones Genes Metastasis Suppressor Genes Cell Matrix Degradative Genes Immune Modularity Immune Re
Slide 28: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate T| Patent Portfolio: 39 issued patents; a Olvi-Vec covered by Composition of Matter . (2031) and Manufacturing (2038) Strong IP “~~ Olvi-Vec: Worldwide operating freedom; Regulato ry . No third-party royalties due Designations (oO Long D
Slide 29: Accomplished Leadership Team
Accomplished Leadership Team Executive Team @ 9 Thomas Zindrick, JD Paul Scigalla, MD, PhD ‘THOMAS ZINDRICK, JD Doug Samuelson ‘Sean Ryder, JD ‘Chairman of the Board Chie Executive Officer Chief Medical officer Chief Financial Officer General Counsel AMGEN Pfizer HT HELSINN JAMES L. TYREE, MBA aeror
Slide 30: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Executed Milestones IN Executed on go public strategy J and follow on with $60M raised (@) Initation of Phase 3 Trial in t ) PRROC Phase 2 results published in JAMA Oncology e aA Collaboration and License agreement with New
Slide 31: Expected Operating Runway into 1Q 2026
Expected Operating Runway into 1Q 2026 Capitalization Summary Analyst Coverage Stock Symbol GNLX . Bruce Jackson M.S., MBA Share Price”) $35.00 The Benchmark Company Shares Outstanding 25.85M . Kemp Dolliver CFA BROOKLINE CAPITAL MARKETS Market Capitalization”) $892M . 2023 Financing Events Cash & E
Slide 32: Highlights of Genelux Execution
Highlights of Genelux Execution Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICE™ Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgene
Slide 33: Redefining Immuno-Oncology
@HeNeELU™x Redefining Immuno-Oncology Corporate Presentation | June 2023